- freely available
Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents
AbstractSmallpox is an acute disease caused by infection with variola virus that has had historic effects on the human population due to its virulence and infectivity. Because variola remains a threat to humans, the discovery and development of novel pox therapeutics and vaccines has been an area of intense focus. As variola is a uniquely human virus lacking a robust animal model, the development of rational therapeutic or vaccine approaches for variola requires the use of model systems that reflect the clinical aspects of human infection. Many laboratory animal models of poxviral disease have been developed over the years to study host response and to evaluate new therapeutics and vaccines for the treatment or prevention of human smallpox. Rabbitpox (rabbitpox virus infection in rabbits) is a severe and often lethal infection that has been identified as an ideal disease model for the study of poxviruses in a non-rodent species. The aerosol infection model (aerosolized rabbitpox infection) embodies many of the desired aspects of the disease syndrome that involves the respiratory system and thus may serve as an appropriate model for evaluation of antivirals under development for the therapeutic treatment of human smallpox. In this review we summarize the aerosol model of rabbitpox, discuss the development efforts that have thus far used this model for antiviral testing, and comment on the prospects for its use in future evaluations requiring a poxviral model with a focus on respiratory infection.
Share & Cite This Article
Roy, C.J.; Voss, T.G. Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents. Viruses 2010, 2, 2096-2107.View more citation formats
Roy CJ, Voss TG. Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents. Viruses. 2010; 2(9):2096-2107.Chicago/Turabian Style
Roy, Chad J.; Voss, Thomas G. 2010. "Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents." Viruses 2, no. 9: 2096-2107.